We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2024 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Antigen Test Boosts Detection of Primary Biliary Cirrhosis

By LabMedica International staff writers
Posted on 30 Jun 2010
A new enzyme-linked immunosorbent assay (ELISA) significantly increases the serological detection rate for primary biliary cirrhosis (PBC).

The assay, which is based on a designer recombinant fusion protein, provides unparalleled sensitivity for detection of autoantibodies against the mitochondrial antigen M2 (AMA-M2) in the diagnosis of primary PBC.

The novel fusion protein combines the immunogenic domains of all three relevant enzyme complexes (3E) of the M2 antigen, presenting them in a defined stoichiometric relationship. This designer antigen is used together with the classical target antigen native pyruvate dehydrogenase in the new EUROIMMUN (Luebeck, Germany) anti-M2-3E ELISA. The extended antigen spectrum and the resulting increase in diagnostic efficiency make the test a powerful new tool for PBC diagnostics.

In a study with 170 sera from clinically characterized PBC patients the new Anti-M2-3E ELISA demonstrated a 14% higher sensitivity than a conventional Anti-M2 ELISA.

The Anti-M2-3E ELISA is easy to perform and, like other EUROIMMUN ELISAs, can be fully automated on the company's Analyzer I and I-2P systems. These flexible instrument systems offer reliable automated processing of an extensive range of validated parameters for autoimmune diagnostics, infectious serology, and allergology.

PBC is an immune-mediated chronic inflammatory cholestatic liver disease of unknown etiology. Up to 94% of patients exhibit AMA-M2 and these constitute the most important serological marker. The majority of M2-specific autoantibodies are directed against the enzyme pyruvate dehydrogenase, and many commercial ELISAs are based solely on this main target antigen. However, 5-10% of patients exhibit only antibodies against the other two main autoantigens of the M2 complex, namely branched-chain 2-oxoacid dehydrogenase and oxoglutarate dehydrogenase, and are therefore not detected with conventional tests.

EUROIMMUN produces a wide range of reagents for medical laboratory diagnostics. The main focus is on test systems for antibodies in patient serum. These allow highly sensitive and specific diagnosis of autoimmune diseases, infectious diseases, and allergies.

Related Links:
EUROIMMUN



New
Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Automated Blood Typing System
IH-500 NEXT
New
Urine Strips
11 Parameter Urine Strips
New
Vitamin B12 Test
CHORUS CLIA VIT B12

Latest Immunology News

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Advanced Imaging Method Maps Immune Cell Connections to Predict Cancer Patients Survival

Computational Tool Predicts Immunotherapy Outcomes for Metastatic Breast Cancer Patients